Does Rallies show 13F holders for ALLO?

Yes. Rallies tracks hedge fund and 13F ownership data for ALLO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALLO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALLO. It does not provide personalized investment advice.

ALLO (Allogene Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Allogene Therapeutics, Inc. Common Stock (ALLO) is a publicly traded Healthcare sector company. As of May 21, 2026, ALLO trades at $1.92 with a market cap of $669.60M and a P/E ratio of -2.17. ALLO moved +0.53% today. Year to date, ALLO is +40.74%; over the trailing twelve months it is +63.79%. Its 52-week range spans $0.86 to $4.46. Analyst consensus is strong buy with an average price target of $8.71. Rallies surfaces ALLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALLO stock?

Hedge funds tracked by Rallies that own ALLO include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Allogene Therapeutics, Inc. Common Stock.

ALLO Key Metrics

Key financial metrics for ALLO
Metric	Value
Price	$1.92
Market Cap	$669.60M
P/E Ratio	-2.17
EPS	$-0.87
Dividend Yield	0.00%
52-Week High	$4.46
52-Week Low	$0.86
Volume	9.12K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-190.89M
Gross Margin	0.00%

Top Hedge Funds Holding ALLO

Exoduspoint Capital holds 64.31K shares of ALLO, changed -96.07% as of Mar 31, 2026.

Latest ALLO News

Allogene Therapeutics Q1 Runway Extended, ALLO-501 Posts 65% Response Rate — May 14, 2026
58.3% MRD Clearance in Phase 2 ALPHA3 Trial Bolsters Allogene’s 2029 Cash Runway — May 13, 2026
Allogene Showcases BCMA/CD70 Dual AlloCAR T Data and Dagger® Autoimmune Platform at AACR 2026 — Apr 20, 2026
Allogene Raises $200.4M via 100.2M Share Public Offering — Apr 16, 2026
Allogene’s ALLO-329 Dual CAR T Shows Lupus Model Efficacy, Phase 1 Data June 2026 — Apr 15, 2026

Recent ALLO Insider Trades

Yoshiyama Annie sold 9.59K (~$22.14K) on Apr 21, 2026.
Beneski Benjamin Machinas sold 2.87K (~$7.17K) on Mar 31, 2026.
Beneski Benjamin Machinas sold 4.83K (~$11.94K) on Mar 16, 2026.

ALLO Analyst Consensus

14 analysts cover ALLO: 0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.71.

Common questions about ALLO

Who owns ALLO stock?: Hedge funds tracked by Rallies that own ALLO include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Allogene Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ALLO?: Yes. Rallies tracks hedge fund and 13F ownership data for ALLO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALLO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALLO. It does not provide personalized investment advice.